Autonomix Medical (NASDAQ: AMIX) has announced new subgroup clinical data from its proof-of-concept study presented at the 2026 ASCO Gastrointestinal Cancers Symposium demonstrating rapid, durable, and meaningful pain relief observed in Stage 2 through Stage 4 pancreatic cancer, including late-stage patients with limited treatment options.
According to Autonomix, the analysis expands upon previously reported data from the company’s ongoing clinical evaluation of its first-in-class platform system technology, which includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with greater sensitivity than currently available technologies. The company is initially developing this technology for the treatment of pain focused on pancreatic cancer.
In a statement, Brad Hauser, president and CEO of Autonomix, commented, “Pancreatic cancer pain remains one of the most debilitating and undertreated aspects of oncology care. Seeing patients move from severe pain to mild or near-elimination levels of pain, even in the most advanced stages of pancreatic cancer, is extraordinarily encouraging. These findings reinforce our belief that a targeted, nerve-based approach has the potential to provide meaningful relief when traditional pharmacologic and interventional options fall short.”
